Progression of benign prostatic hyperplasia: Systematic review of the placebo arms of clinical trials

BJU International

Volumn 102, Issue 8, 2008, Pages 981-986

  Emberton, Mark ^b   Fitzpatrick, John M ^d   Garcia Losa, Manuel ^e   Qizilbash, Nawab ^a,c   Djavan, Bob ^f  

^a OXON Epidemiology Ltd   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e GLAXOSMITHKLINE   (Spain)

^f UNIVERSITY OF VIENNA   (Austria)

Author keywords

Benign prostatic hyperplasia; Placebo; Progression; Systematic review; Trials

Indexed keywords

ALFUZOSIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; SAW PALMETTO EXTRACT; TERAZOSIN; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; SABAL; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; URINE FLOW RATE; URINE RETENTION;

ADULT; AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; URINARY RETENTION;

EID: 52749099638     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07717.x     Document Type: Article

References (26)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991 338 : 469 71
2. Rhodes T, Girman CJ, Jaconsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 1999 161 : 1174
3. Homma Y, Imago C, Takahahi S, Kawabe K, Aso Y. Urinary symptoms and urodynamics in a normal elderly population. Scand J Urol Nephrol (Suppl) 1994 157 : 27
4. Williams AM, Simon I, Landis PK et al. Prostates growth rate determined from MRI data: age-related longitudinal changes. J Androl 1999 20 : 474
5. Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50-78 years: the Krimpen Study. Eur Urol 2004 46 : 753 9
6. Roehrborn CG, McConnell JD, Lieber MM et al., for the PLESS Study Group. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999 53 : 473 80
7. McConnell JD, Roehrborn CG, Bautista OM et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98
8. Marks LS, Roehrborn CG, Andriole GL. Prevention of Benign Prostatic Hyperplasia Disease. J Urol 2006 176 : 1299 306
9. StataCorp. Stata Statistical Software: Release 8. College Station, TX : StataCorp LP, 2003
10. Andersen JT, Ekman P, Wolf H et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995 46 : 631 7
11. Bent S, Kane C, Shinohara K et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006 354 : 557 66
12. Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY, on behalf of the CUSP Investigators. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study. Clin Ther 1995 17 : 956 69
13. Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993 22 : 291 9
14. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 1992 327 : 1185 91
15. Kirby RS, Roehrborn C, Boyle P et al., Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 61 : 119 26
16. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996 335 : 533 9
17. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. The PROWESS Study Group. Urology 1998 51 : 677 86
18. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. The Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998 338 : 612 3
19. Nickel JC, Fradet Y, Boake RC et al., the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996 155 : 1251 9
20. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996 47 : 159 68
21. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, on behalf of the ARIA 3001, ARIA 3002 and ARIA 3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60 : 434 41
22. Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006 97 : 734 41
23. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther 1997 19 : 243 58
24. Emberton M, Hartung R, Matzkin H et al. Symptomatic progression under treatment and history of AUR are the strongest predictors for AUR in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005 66 : 316 22
25. Roberts RO, Lieber MM, Jacobson DJ, Girman CJ, Jacobsen SJ. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 2005 80 : 759 64
26. Souverein PC, van Riemsdijk MM, de la Rosette JJ, Opdam PC, Leufkens HG. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. Eur Urol 2004 47 : 505 10